argenx SE (LTS:0QW0) Change In Receivables : €0 Mil (TTM As of Dec. 2024)

View and export this data going back to 2014. Start your Free Trial

What is argenx SE Change In Receivables?

argenx SE's change in receivables for the quarter that ended in Dec. 2024 was €0 Mil. It means argenx SE's Accounts Receivable stayed the same from Sep. 2024 to Dec. 2024 .

argenx SE's change in receivables for the fiscal year that ended in Dec. 2024 was €-404 Mil. It means argenx SE's Accounts Receivable increased by €404 Mil from Dec. 2023 to Dec. 2024 .

argenx SE's Accounts Receivable for the quarter that ended in Dec. 2024 was €781 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. argenx SE's Days Sales Outstanding for the three months ended in Dec. 2024 was 101.05.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. argenx SE's liquidation value for the three months ended in Dec. 2024 was €3,334 Mil.

argenx SE Change In Receivables Historical Data

The historical data trend for argenx SE's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

argenx SE Change In Receivables Chart

argenx SE Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Receivables

Get a 7-Day Free Trial

18.05

-27.99

-209.81

-170.28

-404.07

argenx SE Quarterly Data
	Sep19	Dec19	Jun20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

argenx SE Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0 Mil.

argenx SE (LTS:0QW0) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

argenx SE's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	780.91	/	705.183	*	91
=	101.05

2. In Ben Graham's calculation of liquidation value, argenx SE's accounts receivable are only considered to be worth 75% of book value:

argenx SE's liquidation value for the quarter that ended in Dec. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	3226.779	-	672.548	+	0.75 * 780.91	+	0.5 * 388.908
=	3,334

argenx SE Change In Receivables Related Terms

Thank you for viewing the detailed overview of argenx SE's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

argenx SE Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » argenx SE (LTS:0QW0) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

ARGX:USA ARGNF:USA ARGXb:UK 1AEA:Germany 1AE:Germany 1AE:Germany A1RG34:Brazil ARGX:Belgium ARGX:Austria

Address

Laarderhoogtweg 25, Amsterdam, NH, NLD, 1101EB

Website

https://www.argenx.com

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

argenx SE Headlines

No Headlines